- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01752660
Exercise in Severely Disabled Patients With MS
Endurance Training in Severely Disabled Patients With MS - a Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For many years, patients with multiple sclerosis (MS) have been advised not to participate in physical exercise. This advice was given in part because some patients were reported to experience symptom instability during exercise as a consequence of increased body temperature. A further argument was that avoiding exercise would preserve energy and thereby result in less fatigue, leaving more energy for activities of daily living. During the last decade, it has been more common to recommend exercise for MS patients, because of its recently proven beneficial effects in these patients.
Resistance- and endurance training constitutes the two extremes of basic physical exercise. To gain insight into the effects of exercise it therefore makes sense to understand the extremes. In mild to moderately impaired MS patients endurance training is well tolerated and providing beneficial effects. However, this exercise modality has not yet been tested in severely disabled patients, and it is therefore unclear if endurance training is feasible and beneficial in these patients. The investigators have, therefore, designed a feasibility study evaluating the effects of 4 weeks of endurance training in severely disabled MS patients (Expanded Disability Status Scale score > 6).
Patients are inpatients at one of the national MS hospitals and endurance training is added to the usual care, and compared to usual care only (control group). Exercise frequency is 3 times per week, and intensity is controlled by HR measurements during exercise.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jylland
-
Ry, Jylland, Denmark, 8680
- MS Hospital in Ry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Signed informed consent
->18 years
- Primary progressive or secondary progressive MS according to the McDonald criteria
- 6.5 ≤ EDSS ≤ 8.0 and pyramidal score between 1 and 4
- Maximal walking distance ≤ 10m
Exclusion Criteria:
- Patients are excluded if they:
- have dementia,alcoholism, or pacemaker treatment
- any serious medical comorbidities
- are pregnant
- have done systematic endurance training (>1day/week) within the last 3 months.
- complete less than 80% of the planned training sessions
- medical conditions that exclude performance of a maximal endurance test.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Endurance training
Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
|
Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
|
|
Active Comparator: Standard care
Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
|
Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise compliance
Time Frame: Exercise compliance is registered immediatly after all planned exercise sessions during the 4 week intervention
|
Compliance to exercise is registered and serve as the primary outcome.
|
Exercise compliance is registered immediatly after all planned exercise sessions during the 4 week intervention
|
|
Drop out rate
Time Frame: Number of participants who drop out is registered at the post measurement just after the intervention.
|
Number of participants who drop out is registered at the post measurement just after the intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak oxygen consumption
Time Frame: 1-2 day before the intervention and 1-2days after the 4 week intervention peak oxygen is measured
|
Measurement of peak oxygen consumption during a ramp protocol on armergometer.
|
1-2 day before the intervention and 1-2days after the 4 week intervention peak oxygen is measured
|
|
Box and Block test
Time Frame: 1-2 day before the intervention and 1-2days after the 4 week intervention the box and block test is performed
|
1-2 day before the intervention and 1-2days after the 4 week intervention the box and block test is performed
|
|
|
Sit to stand test
Time Frame: 1-2 day before the intervention and 1-2days after the 4 week intervention the sit to stand test is performed
|
1-2 day before the intervention and 1-2days after the 4 week intervention the sit to stand test is performed
|
|
|
Handgrip test
Time Frame: 1-2 day before the intervention and 1-2days after the 4 week intervention the handgrip test is performed
|
1-2 day before the intervention and 1-2days after the 4 week intervention the handgrip test is performed
|
|
|
Wheel-chair test
Time Frame: 1-2 day before the intervention and 1-2days after the 4 week intervention the wheel-chair test is performed
|
1-2 day before the intervention and 1-2days after the 4 week intervention the wheel-chair test is performed
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ulrik Dalgas, PhD, Dep. Public Health, Aarhus University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UAarhus100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Endurance training
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany
-
General University Hospital, PragueRecruitingParkinson Disease, IdiopathicCzech Republic
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Pulmonary DiseaseGermany
-
Riphah International UniversityRecruitingHockey | Plyometric Exercise | Endurance TrainingPakistan
-
University Hospital HeidelbergDietmar Hopp Stiftung; Friederike Rosenberger (University Hospital Heidelberg)...Completed
-
General Committee of Teaching Hospitals and Institutes...Cairo University; Taibah UniversityCompleted
-
University of ViennaCompletedCOVID-19 | Post-COVID-19 Syndrome | Long COVID-19Austria
-
Landsteiner InstitutLund University; Medical University of Vienna; Mein Hanusch-Krankenhaus; Fondazione... and other collaboratorsCompletedType 2 Diabetes Mellitus | Insulin ResistanceAustria
-
Universität des SaarlandesThe German Heart FoundationCompletedChronic Heart Failure | Dilated CardiomyopathyGermany
-
Charite University, Berlin, GermanyUnknownHeart Failure | Sudden Cardiac Death | Cardiac Resynchronisation TherapyGermany